Journals / Haseki Tıp Bülteni / 2015 / Cilt: 53 - Sayı: 4

The Challenges for the Diagnosis and Treatment of Sleep Disorders in Turkey

Ülkemizde Uyku Bozukluklarının Teşhis ve Tedavisinin Yaygınlaşmasının Önündeki Engeller

Pages
283–285
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We assume that hospitals should establish their own patient follow-up units, as such in home care system, for providing PAP devices and submit reports for periodic follow-up and utilization of PAP devices to the social security system on a regular basis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The reason for extra long waiting periods for in-lab polysomnography (PSG) in thousands of patients is the fact that only full PSG analysis and reports are acceptable for the diagnosis of sleep disorders in Turkey.
📊
Key Findings & Data:There have been reports showing that portable polygraphy (PG) had the same accuracy with PSG in 80% of patients.
💡
Conclusion & Impact:We assume that hospitals should establish their own patient follow-up units, as such in home care system, for providing PAP devices and submit reports for periodic follow-up and utilization of PAP devices to the social security system on a regular basis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The reason for extra long waiting periods for in-lab polysomnography (PSG) in thousands of patients is the fact that only full PSG analysis and reports are acceptable for the diagnosis of sleep disorders in Turkey. There have been reports showing that portable polygraphy (PG) had the same accuracy with PSG in 80% of patients. Sleep studies are performed with the frequency of 90% for PSG and 10% for PG in Turkey while vice versa in the most European countries. The health practices communiqué (HPC) and performance-based payment for the diagnosis of sleep disorders are unsatisfactory for the stakeholders. Ten to twenty thousand positive airway pressure (PAP) devices are prescribed per year after obligatory in-lab PSG tests in Turkey. However, treatment efficacy of these PAP devices which patients are provided or patients obtain themselves with the prices determined by the HPC are not followed up. We assume that hospitals should establish their own patient follow-up units, as such in home care system, for providing PAP devices and submit reports for periodic follow-up and utilization of PAP devices to the social security system on a regular basis.

Özet

Tüm uyku bozukluklarının teşhisinde tek geçerli incelemenin sadece uyku laboratuvarında yapılan polisomnografi (PSG) kabul edilmesi, ülkemizde binlerce hastanın tanı için bir yılı aşkın beklemesine yol açmaktadır. Yapılan bilimsel çalışmalarda PSG önerilen hastaların %80'ine poligrafi (PG) ile tetkik yapıldığında PSG ile aynı doğrulukta teşhis konulduğu gösterilmiştir. Ülkemizdeki uyku çalışmaları %90 PSG, %10 PG ile yapılmaktadır. Avrupa genelinde ise %10 PSG, %90 PG ile yapılmaktadır. Uyku bozukluklarının teşhislerinin Sağlık Uygulama Tebliği (SUT) ve performans karşılıkları ise taraflar için yeterli görülmemektedir. Yapılan uyku tetkikleri sonucunda ülkemizde her yıl 10 ile 20 bin civarında hastaya pozitif hava basıncı (PHB) tedavisi önerilmektedir. Ancak bu hastalara verilen veya hastaların SUT fiyatları doğrultusunda temin ettikleri cihazların tedavideki verimliliği takip edilmemektedir. Çözüm olarak; PHB cihazlarının temini için evde bakım birimlerinin yapılanmasında olduğu gibi, hastanelerin kendi tedavi ettikleri hastalar için hasta takip birimi kurmalarıdır. Hastanelerin düzenli olarak Sosyal Güvenlik Kurumu'na (SGK) takip ve kullanım raporlarını göndermeleri ve hastanın ihtiyacına göre uyumlu olduğu cihazı kendi bünyelerinde temin etmeleri en uygun çözüm gibi görünmektedir.

🔖

Cite This Article

ÖZKUL, M. H. (2015). The Challenges for the Diagnosis and Treatment of Sleep Disorders in Turkey. Haseki Tıp Bülteni, Cilt: 53 - Sayı: 4, 283–285. https://ajindex.com/articles/267845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Hiestand DM, Britz P, Goldman M, Phillips B. Prevalence of symptoms and risk of sleep apnea in the US population: Results from the national sleep foundation sleep in America 2005 poll. Chest 2006;130:780-6
  2. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39
  3. Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. JAMA 2004;291:2013-6
  4. Bresnitz EA, Goldberg R, Kosinski RM. Epidemiology of obstructive sleep apnea. Epidemiol Rev 1994;16:210-27
  5. Özkul MH, Chatzi T.Yaşar H, Acar G, Gezginadam Z. Uyku apnesi hastalarında gündüz aşırı uykululuk halinin değerlendirilmesi ve hayat kalitesi ile olan ilişkisinin saptanması. İçinde: Metin S, editör. Kongre kitapçığı
  6. Ulusal Havacılık Kongresi 2015 28-30 Mart; Teknopark, İstanbul Türkiye; 2015
  7. Stutts J, Wilkins JW, Osberg JS, Vaughn BV. Driver risk factors for sleep-related crashes. Accid Anal Prev 2003;35:321-31
  8. Teran-Santos J, Jimenez-Gomez A, Cordero-Guavera J. The association between sleep apnea and risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 1999;340:847-51
  9. Gillberg M, Kecklund G, Akerstedt T. Sleepiness and performance of professional drivers in a truck simulatorcomparisons between day and night driving. J Sleep Res 1996;5:12-5
  10. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003;290:1906-14
  11. Skinner MA, Choudhury MS, Homan SD, Cowan JO, Wilkins GT, Taylor DR. Accuracy of monitoring for sleep-related breathing disorders in the coronary care unit. Chest 2005;127:66-71
  12. Dingli K, Coleman EL, Vennelle M, et al. Evaluation of a portable device for diagnosing the sleep apnoea/hypopnoea syndrome. Eur Respir J 2003;21:253-9
  13. Favier B. Sleep diagnostic overview/trends. Marketing development manager diagnostic ASV & Co-morbidity 2011.